Clinical Trial Update: Tisleizumab Combined With Lenvatinib and XELOX Regimen (Oxaliplatin Combined With Capecitabine) in the First-line Treatment of Advanced and Unresectable Biliary Tract Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating tisleizumab with lenvatinib and XELOX in first-line treatment of advanced unresectable biliary tract tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer
• Cholangiocarcinoma
• Gallbladder Cancer

Drugs mentioned

• Lenvatinib (lenvatinib)
• XELOX regimen
• tisleizumab (tisleizumab)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Biliary Tract Tumor | Phase 2 | Status: UNKNOWN